Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRMD CorMedix	$14.83 +3.3%	$12.32	$5.31 ▼ $17.43	$1.07B	1.71	3.65 million shs	2.67 million shs
CRON Cronos Group	$2.60	$2.19	$1.60 ▼ $2.77	$995.90M	1.01	3.92 million shs	5.83 million shs
PRAX Praxis Precision Medicines	$45.54 -1.0%	$49.18	$26.70 ▼ $91.83	$967.90M	2.62	508,628 shs	275,873 shs
VOR Vor Biopharma	$1.97 -2.0%	$1.96	$0.13 ▼ $3.29	$249.57M	2.06	7.79 million shs	3.65 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRMD CorMedix	+1.49%	+5.83%	+23.28%	+18.89%	+138.37%
CRON Cronos Group	+1.56%	+1.56%	+29.35%	+31.31%	+20.93%
PRAX Praxis Precision Medicines	-1.98%	-0.84%	-17.82%	+19.21%	-9.93%
VOR Vor Biopharma	+0.50%	-7.37%	-14.47%	+905.50%	+133.72%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRMD CorMedix	2.8186 of 5 stars	3.4	1.0	4.2	0.0	1.9
CRON Cronos Group	0.8038 of 5 stars	0.0	3.0	2.5	0.0	1.3
PRAX Praxis Precision Medicines	1.7337 of 5 stars	3.4	1.0	2.8	1.7	0.0
VOR Vor Biopharma	1.9549 of 5 stars	3.3	0.0	1.1	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRMD CorMedix	2.86	Moderate Buy	$17.33	16.88% Upside
CRON Cronos Group	0.00	N/A	N/A	N/A
PRAX Praxis Precision Medicines	2.75	Moderate Buy	$85.88	88.57% Upside
VOR Vor Biopharma	2.56	Moderate Buy	$6.07	207.95% Upside

Current Analyst Ratings Breakdown

Latest VOR, PRAX, CRMD, and CRON Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/14/2025	VOR Vor Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00
8/8/2025	CRMD CorMedix	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$20.00 ➝ $17.00
8/5/2025	PRAX Praxis Precision Medicines	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$105.00 ➝ $115.00
7/29/2025	PRAX Praxis Precision Medicines	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00
7/18/2025	PRAX Praxis Precision Medicines	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$105.00
7/8/2025	PRAX Praxis Precision Medicines	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$97.00 ➝ $115.00
6/30/2025	CRMD CorMedix	D Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/30/2025	CRMD CorMedix	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold
6/30/2025	CRMD CorMedix	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$20.00
6/30/2025	VOR Vor Biopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$3.00
6/26/2025	VOR Vor Biopharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Outperform

(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRMD CorMedix	$43.47M	25.47	N/A	N/A	$2.96 per share	5.01
CRON Cronos Group	$117.61M	8.47	$0.00 per share	5,587.55	$2.95 per share	0.88
PRAX Praxis Precision Medicines	$8.55M	112.12	N/A	N/A	$19.21 per share	2.37
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRMD CorMedix	-$17.93M	$0.75	19.77	15.78	N/A	42.11%	42.73%	34.19%	10/29/2025 (Estimated)
CRON Cronos Group	$41.08M	$0.05	52.00	86.67	N/A	14.19%	-3.78%	-3.62%	11/11/2025 (Estimated)
PRAX Praxis Precision Medicines	-$182.82M	-$12.29	N/A	N/A	N/A	-2,137.48%	-60.07%	-54.84%	11/5/2025 (Estimated)
VOR Vor Biopharma	N/A	-$13.66	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest VOR, PRAX, CRMD, and CRON Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	CRMD CorMedix	$0.20	$0.28	+$0.08	$0.28	$29.88 million	$39.74 million
8/7/2025	Q2 2025	CRON Cronos Group	-$0.02	-$0.10	-$0.08	-$0.10	$45.73 million	$33.46 million
8/4/2025	Q2 2025 & Study Result	PRAX Praxis Precision Medicines	-$3.40	-$3.31	+$0.09	-$3.31	$0.15 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRMD CorMedix	N/A	N/A	N/A	N/A	N/A
CRON Cronos Group	N/A	N/A	N/A	N/A	N/A
PRAX Praxis Precision Medicines	N/A	N/A	N/A	N/A	N/A
VOR Vor Biopharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRMD CorMedix	N/A	7.82	7.52
CRON Cronos Group	N/A	24.65	23.53
PRAX Praxis Precision Medicines	N/A	6.31	6.31
VOR Vor Biopharma	N/A	N/A	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRMD CorMedix	34.18%
CRON Cronos Group	8.71%
PRAX Praxis Precision Medicines	67.84%
VOR Vor Biopharma	97.29%

Insider Ownership

Company	Insider Ownership
CRMD CorMedix	5.30%
CRON Cronos Group	7.30%
PRAX Praxis Precision Medicines	2.70%
VOR Vor Biopharma	0.45%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRMD CorMedix	30	74.65 million	70.69 million	Optionable
CRON Cronos Group	450	383.04 million	355.08 million	Optionable
PRAX Praxis Precision Medicines	110	21.05 million	20.48 million	Optionable
VOR Vor Biopharma	140	126.68 million	65.45 million	Not Optionable

VOR, PRAX, CRMD, and CRON Headlines

Recent News About These Companies

Vor Biopharma (NYSE:VOR) Major Shareholder Reprogrammed Interchange Llc Sells 284,190 Shares

August 28 at 8:06 AM | insidertrades.com

Vor Biopharma shares rise after collaborator’s IgAN therapy meets Phase 3 endpoint

August 28 at 6:58 AM | msn.com

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for IgA Nephropathy

August 27 at 8:00 AM | globenewswire.com

Vor Biopharma Inc. (NYSE:VOR) Receives $6.07 Average PT from Brokerages

August 27 at 2:55 AM | americanbankingnews.com

Vor Bio to Participate in Upcoming Investor Conferences

August 26 at 8:00 AM | globenewswire.com

Vor Biopharma Inc. (NYSE:VOR) Receives Consensus Recommendation of "Moderate Buy" from Analysts

August 26 at 2:25 AM | marketbeat.com

Vor Biopharma: Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 19, 2025 | finanznachrichten.de

Q3 EPS Estimates for Vor Biopharma Reduced by HC Wainwright

August 19, 2025 | marketbeat.com

Vor Biopharma Q3 EPS Forecast Decreased by HC Wainwright

August 19, 2025 | americanbankingnews.com

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 18, 2025 | globenewswire.com

Analysts Set Expectations for Vor Biopharma FY2028 Earnings

August 17, 2025 | marketbeat.com

Wedbush Brokers Boost Earnings Estimates for Vor Biopharma

August 17, 2025 | marketbeat.com

Vor Biopharma (NYSE:VOR) Receives "Buy" Rating from HC Wainwright

August 16, 2025 | marketbeat.com

Vor Biopharma Shares Soar on Positive Results for Autoimmune-Disorder Treatment

August 13, 2025 | marketwatch.com

Vor says drug licensed from RemeGen succeeded in Sjögren’s study

August 13, 2025 | finance.yahoo.com

Vor Bio Rallies On Strong Data For Autoimmune Drug Candidate

August 13, 2025 | benzinga.com

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor

August 13, 2025 | globenewswire.com

Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer

August 4, 2025 | globenewswire.com

Vor Biopharma (NYSE:VOR) Trading Down 2.9% - Time to Sell?

July 30, 2025 | marketbeat.com

Vor Biopharma Inc. (NYSE:VOR) Receives Consensus Rating of "Moderate Buy" from Brokerages

July 30, 2025 | marketbeat.com

Vor Biopharma (VOR) Jumps 10% on Addition of 2 CEOs to Board

July 29, 2025 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

VOR, PRAX, CRMD, and CRON Company Descriptions

CorMedix NASDAQ:CRMD

$14.83 +0.48 (+3.34%)

Closing price 04:00 PM Eastern

Extended Trading

$14.88 +0.04 (+0.30%)

As of 07:55 PM Eastern

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

Cronos Group NASDAQ:CRON

$2.60 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$2.58 -0.02 (-0.58%)

As of 07:57 PM Eastern

Cronos Group Inc. operates as a cannabinoid company that engages in the cultivation, production and marketing of cannabis products in Canada, Israel, and Germany. It offers dried flower, pre-rolls, oils, vaporizers, edibles, and cannabis tinctures under the Spinach, Lord Jones, and PEACE NATURALS brands. Cronos Group Inc. was founded in 2012 and is based in Toronto, Canada.

Praxis Precision Medicines NASDAQ:PRAX

$45.54 -0.45 (-0.98%)

Closing price 04:00 PM Eastern

Extended Trading

$45.52 -0.02 (-0.05%)

As of 05:38 PM Eastern

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Vor Biopharma NYSE:VOR

$1.97 -0.04 (-1.99%)

Closing price 04:00 PM Eastern

Extended Trading

$2.00 +0.03 (+1.27%)

As of 07:59 PM Eastern

Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies. The company is also developing Mylotarg, a CD33-directed antibody drug conjugate (ADC) therapy for patients with leukemia; VCAR33, a CAR-T therapy designed to target CD33, a clinically validated target for AML, which are under preclinical and Phase 1/2 clinical studies; trem-cel + VCAR33 treatment system that is under preclinical studies for the treatment of AML; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-engineered eHSC and CD33-CLL1 multi-specific CAR-T, which are under preclinical studies for the treatment of AML. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time